Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare Conference
June 07 2017 - 8:00AM
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced that it will provide a corporate
overview, including an update on the timing of regulatory
submissions for marketing approval for M923, its biosimilar HUMIRA®
(adalimumab) candidate, at the Goldman Sachs 38th Annual Global
Healthcare Conference. The presentation is scheduled for Wednesday,
June 14th at 11:20 a.m. PT/2:20 p.m. ET.
A webcast of the presentation will be available
live on the “Investors” section of the company’s website located at
www.momentapharma.com. A replay of the presentation will be
posted on the Momenta website approximately one hour after the
event.
About MomentaMomenta
Pharmaceuticals is a biotechnology company specializing in the
detailed structural analysis of complex drugs and is headquartered
in Cambridge, MA. Momenta is applying its technology to
the development of generic versions of complex drugs, biosimilar
and potentially interchangeable biologics, and to the discovery and
development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does
not form a part of this press release.
Our logo, trademarks, and service marks are the
property of Momenta Pharmaceuticals, Inc. All other trade names,
trademarks, or service marks are property of their respective
owners.
Forward-Looking
StatementsStatements in this press release regarding
management’s future expectations, beliefs, intentions, goals,
strategies, plans or prospects, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including but not limited to statements regarding
providing a corporate overview and updating the timing of
regulatory submissions. Forward-looking statements may be
identified by words such as “believe,” “continue,” “could,”
“expect,” “guidance,” “may,” “plan,” “potential,” “target,” “will”
and other similar words or expressions, or the negative of these
words or similar words or expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors, including those referred to under the section “Risk
Factors” in the Company’s Quarterly Report on Form 10-Q for the
year ended March 31, 2017, filed with the Securities and Exchange
Commission, as well as other documents that may be filed by the
Company from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and factors,
the Company’s actual results may differ materially from any future
results, performance or achievements discussed in or implied by the
forward-looking statements contained herein. The Company is
providing the information in this press release as of this date and
assumes no obligations to update the information included in this
press release or revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Sep 2023 to Sep 2024